The Morrison Government is investing $5 million in an Australian first genomics project to support personalised treatments for patients with lung cancer. The ground-breaking ‘ASPiRATION’ project is a genomic profiling research project for 1,000 Australians with newly diagnosed metastatic, non-squamous, non-small cell lung cancer. The study is jointly funded by the Federal Government through the $20 billion Medical Research Future Fund (MRFF) and by the biopharmaceutical company, Roche. Each patient will have their particular disease individually tested in a process known as comprehensive genomic profiling. This information will then be used to improve and optimise treatment decisions by identifying the right treatment for the right patient, at the right time. Patients participate in clinical trials for substantially life-prolonging targeted therapies. Targeted therapies reduce side effects, avoid unnecessary treatments and offer new hope. It will also serve as a blueprint for how precision medicine, enabled by genomics, can become a […]